TL;DR
This paper introduces PhylEx, a novel computational method that integrates bulk DNA sequencing and single-cell RNA sequencing (scRNA-seq) data to reconstruct the evolutionary history (clonal tree) of cancer. PhylEx not only accurately identifies cancer cell clones and their genetic makeup but also assigns gene expression profiles to these clones, enabling a deeper understanding of cancer's "phylo-phenotypic" landscape.
What Problem Does This Paper Address?
Cancer is a complex evolutionary process where cells accumulate mutations and diversify into distinct clonal populations. Understanding this evolutionary tree (clonal tree) is crucial for diagnosing and treating cancer. Traditional methods relied on bulk DNA sequencing, which can be ambiguous due to the mixture of cells. While single-cell DNA sequencing (scDNA-seq) improved resolution, it still faced challenges. The advent of scRNA-seq offered a way to study gene expression within individual cells, but integrating this with DNA-based clonal inference was difficult. Existing methods often treated these as separate steps, leading to inefficiencies. This paper addresses the need for a unified approach that leverages both bulk DNA and scRNA-seq data to simultaneously infer clonal structure, genotypes, and functional (expression) profiles, providing a more comprehensive view of cancer evolution.
Methods
PhylEx employs a Bayesian statistical framework. Its core innovation lies in integrating bulk DNA and scRNA-seq data within a single probabilistic model.
- Probabilistic Model: PhylEx models raw read counts from scRNA-seq using a mixture of Beta-Binomial distributions. This is key to handling the inherent sparsity and "burstiness" of single-cell gene expression, particularly accounting for cases where a gene is present but not expressed (monoallelic expression or dropout).
- Tree Inference: It uses a tree-structured stick-breaking process (TSSB) as a prior for inferring the clonal tree, a Bayesian non-parametric approach that learns the tree structure directly from the data.
- SNV Assignment: SNVs are assigned to clones based on a Polya's urn scheme, encouraging SNVs to cluster within clones.
- Cell-to-Clone Assignment: PhylEx infers cell-to-clone assignments and clonal genotypes.
- Integration: Crucially, PhylEx integrates information from both bulk DNA (for variant allele frequencies and copy number information) and scRNA-seq (for gene expression patterns) to improve the accuracy of clonal tree reconstruction and cell assignment. It bypasses the need for explicit variant calling in scRNA-seq data, which can be error-prone.
Datasets
The paper evaluates PhylEx on:
- Simulated Datasets: Used to benchmark performance against existing methods under various evolutionary scenarios, including those with copy number variations and different tree topologies (binary and multifurcating).
- Biological Datasets:
- A well-characterized high-grade serous ovarian cancer (HGSOC) cell line (OV2295 and OV2295R2) with previously determined clonal structure.
- Multi-region HER2+ breast cancer tumor data.
Key Insights and Ideas
- Synergy of Data Types: The most significant insight is that integrating scRNA-seq data with bulk DNA-seq data dramatically improves the accuracy of clonal tree reconstruction, especially in the presence of copy number variations, which often confound bulk DNA-only methods.
- Beyond DNA: Functional Phenotypes: PhylEx moves beyond just reconstructing the genetic lineage. By assigning expression profiles to clones, it enables "phylo-phenotypic" analysis, revealing how evolutionary history correlates with cellular function. This offers a richer interpretation than clustering based on expression alone.
- Robustness to Sparsity: The Beta-Binomial mixture model for scRNA-seq data is a clever way to handle the inherent noise and missing data in single-cell expression, making the method more robust.
- Single-Region Advantage: PhylEx demonstrates that combining single-region bulk DNA-seq with scRNA-seq can achieve comparable or superior results to multi-region bulk DNA-seq alone, which is a significant practical advantage as multi-region sampling is often difficult or impossible.
Key Results
- Superior Clonal Tree Reconstruction: PhylEx consistently outperformed state-of-the-art methods (Canopy, TSSB, B-SCITE, ddClone) on simulated datasets in terms of both tree reconstruction error and V-measure clustering metrics, often by a wide margin (e.g., V-measure of 0.866 ± 0.0018 for PhylEx vs. 0.494 for Canopy on one metric).
- Improved Mutation Clustering: PhylEx also showed superior performance in correctly clustering mutations to their respective clones.
- Real-World Validation: On the HGSOC cell line, PhylEx accurately reconstructed the known clonal tree and demonstrated distinct gene expression profiles for different clones, supporting its phylo-phenotypic analysis capabilities.
- Breast Cancer Insights: Analysis of HER2+ breast cancer data revealed clone-specific mutations and pathways, highlighting the method's utility in identifying driver mutations and understanding spatial heterogeneity.
Limitations and Future Work
- Cell-to-Clone Assignment Correctness: While PhylEx's co-clustering of SNVs and cells suggests correctness, the paper acknowledges that direct evaluation of cell-to-clone assignment accuracy is challenging without ground truth.
- Computational Cost: While not explicitly detailed as a limitation, Bayesian inference methods can be computationally intensive, especially with large datasets.
- Future Directions: The authors suggest extending PhylEx to incorporate subclonal copy number information, which is currently difficult to infer from bulk sequencing alone. They also envision its use in characterizing clones by both somatic mutations and copy number profiles, further enhancing the reconstruction of the full evolutionary trajectory of cancer.
Summary updated